Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylphenidate in adolescent females with borderline personality disorder
ACTRN12609001013257Phase 2Not yet recruiting
- Sponsor
- Concord Hospital
- Start
- Jan 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of methylphenidate in borderline personality disorder (BPD), sponsored by Concord Hospital. Primary endpoint: Clinical Global Impression Scale-Severity. Planned start Jan 2010; status: not yet recruiting.
02
Drugs
methylphenidate
03
Conditions
borderline personality disorder (BPD)
Beyond the preview
Go deeper on ACTRN12609001013257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609001013257.